ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

linzagolix

Also written as “KLH-2109”, “75 mg linzagolix tablet” and “200 mg linzagolix tablet”.

Its studies are mostly in Endometriosis · Leiomyoma · Renal Insufficiency · Hepatic Insufficiency, led by 2 companies.

Drug pageLinzagolix: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 6, 201914 company-led studies, 1 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kissei Pharmaceuticalits history only111 open or runningphase 3since Jun 6, 2019Jul 14, 2011Nov 2027phase 3 · NCT07015268
ObsEva30 open or runningphase 2since May 3, 2016May 3, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of ObsEva only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 3, 2016First study: phase 2 study in EndometriosisFirst studyNCT02778399 · 328 enrolled · United States, Poland, Russian Federation and more
  2. Dec 9, 2017Named linzagolixINNProposed as its International Nonproprietary Name in WHO's List 118 · before, KLH-2109, OBE2109
  3. May 20, 20192 phase 1 studiesNCT03961932, NCT03962049

TargetBeta

GNRHR →read by rule
“Gonadotropin-releasing hormone receptor antagonist; Gonadotropin-releasing hormone receptor antagonist”ChEMBL 37, by rule

Other programs on GNRHR

ProgramCompanyFurthest phaseStudies
LeuprolideruleTakedaphase 439
triptorelinruleIpsenphase 421
GoserelinruleAstraZenecaphase 414
GnRH Antagonist SHR7280Jiangsu HengRui Medicinephase 310
Gonadotropin-Releasing HormoneruleFerring Pharmaceuticalsphase 35
leuprolide mesylateruleforesee-pharmaceuticals-co-ltdphase 33

Studies

All 3 ObsEva leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03962049Hepatic Insufficiency · United States1CompletedOct 23, 201924
NCT03961932Renal Insufficiency · United States1CompletedJan 22, 202033
NCT02778399Endometriosis · United States, Poland, Russian Federation and more2CompletedApr 2018328

How it is read

Names in the registry

  • “KLH-2109”, 11 entries
  • “75 mg linzagolix tablet”, 4 entries
  • “200 mg linzagolix tablet”, 4 entries
  • “Linzagolix”, 2 entries
  • “OBE2109”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.